Updates from the Oberland Capital Team

Press & Media

January 2, 2024

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

May 12, 2023

Humacyte and Oberland Capital Announce Funding Agreement Totaling Up to $160 Million

January 10, 2023

Helsinn Closes Financing Agreement with Oberland Capital

October 13, 2022

Oberland Capital Closes Third Healthcare Royalty and Credit Opportunities Fund at $1.2 Billion Hard Cap

December 14, 2021

Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital

October 4, 2021

Centessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital

December 9, 2020

Mirum Pharmaceuticals and Oberland Capital Announce Up to $210 Million Funding Arrangement

July 1, 2020

Axogen Announces New Seven-Year Financing Agreement with Oberland Capital and Provides Preliminary Second Quarter Revenue Estimate

June 26, 2019

Esperion and Oberland Capital Announce $200 Million Funding Agreement

May 5, 2020

Oberland Capital Raises $1.05 Billion Healthcare Royalty Fund to Invest in Companies Advancing Products in Late-Stage Clinical Development

April 23, 2019

NorthStar Medical Closes $100 Million Financing with Oberland Capital to Expand Domestic Mo-99 Radioisotope Production Capacity and Implement RadioGenix® System Enhancements

March 25, 2019

Curis Sells Portion of Erivedge Royalties to Oberland Capital for up to $135.7 Million

November 1, 2018

Oberland Capital Announces Appointment of Two New Partners and Adds Four Additional Employees

September 6, 2018

Oberland Capital Closes $800 Million Healthcare Royalty and Credit Opportunities Fund at Hard Cap

October 26, 2017

Impact Biomedicines Closes $90 Million Financing with Oberland Capital to Fund Fedratinib Program Advancement

June 29, 2017

Melinta Therapeutics Signs $90 Million Financing Agreement with Oberland Capital to Fund Baxdela™ Commercial Activities and Expansion into Additional Indications

September 9, 2015

Agenus Inc. Completes $115 Million Non-Dilutive Royalty Transaction with Oberland Capital

May 1, 2015

Oxford BioMedica Secures $50 Million Loan Facility with Oberland Capital to Support the Group’s Growth Ambitions

April 22, 2015

Oberland Capital Raises $425 Million Healthcare Royalty and Credit Opportunities Fund; Significantly Exceeds Target

November 13, 2014

AxoGen, Inc. Signs Financing Agreement with Oberland Capital
These endorsements are provided by certain executives of portfolio companies that are owned by certain investment vehicles advised by Oberland Capital. None of the executives were compensated for providing these endorsements. As a result of the ownership structure of these portfolio companies, a conflict of interest exists because the executives have an incentive to make positive statements about Oberland Capital and their experiences with Oberland Capital to maintain goodwill with Oberland Capital.